FAQ on Soligenix Inc.'s Phase 2a SGX945 Study for Behçet’s Disease

What is SGX945 and what disease does it target?

SGX945 (dusquetide) is a treatment developed by Soligenix Inc. targeting Behçet’s Disease, a rare inflammatory condition, as part of its innate defense regulator (IDR) technology portfolio.

How effective was SGX945 in the Phase 2a study?

In the Phase 2a study, SGX945 achieved a 40% improvement in the primary ulcer endpoint compared to a historical placebo group, with benefits persisting through the follow-up period and no treatment-related adverse events reported.

What are the next steps for SGX945 following this study?

Soligenix plans to advance SGX945, including reformulating it for home-based subcutaneous administration, to address unmet needs in Behçet’s Disease and other innate immune-related inflammatory conditions.

Who is involved in the development of SGX945?

Soligenix Inc., a late-stage biopharmaceutical company, is developing SGX945, with CEO Christopher J. Schaber leading the efforts to commercialize treatments for rare diseases with unmet medical needs.

Where can I find more information about the Phase 2a study results?

The full press release detailing the Phase 2a study results can be viewed at https://ibn.fm/FqcXf.

What other treatments is Soligenix developing?

Soligenix is also developing HyBryte™ for cutaneous T-cell lymphoma, SGX942 for inflammatory diseases like oral mucositis, and vaccines for ricin toxin, filoviruses, and COVID-19 under its Public Health Solutions business segment.

How does SGX945 compare to apremilast (Otezla®)?

SGX945 matched or exceeded the outcomes of apremilast in the Phase 2a study, despite treatment stopping at four weeks, indicating its potential as an effective treatment for Behçet’s Disease.

What is the significance of the Phase 2a study results?

The results demonstrate SGX945’s biological efficacy and safety, supporting its advancement as a promising treatment for Behçet’s Disease and potentially other inflammatory conditions.

Where can I find more updates on Soligenix Inc.?

Updates on Soligenix Inc. (NASDAQ: SNGX) are available in the company’s newsroom at https://ibn.fm/SNGX.